Redeye updates its estimates and fair value range following BICO’s Q3 2025 report showing a return to organic growth in line with our projec...
Redeye provides its initial comments on BICO following its Q3 results, which came in above expectations overall.
Redeye provides a preview of its estimates ahead of BICO’s Q3 results, scheduled for release on November 4.
Redeye initiates coverage of BICO, a leading player in the bioconvergence space.
